|
WO2021022229A1
|
|
Populations of natural killer cells comprising a cleavage resistant cd16
|
|
WO2021016621A1
|
|
Populations of natural killer cells comprising a cd38 chimeric antigen receptor
|
|
WO2020257720A1
|
|
Exosomes for disease treatment
|
|
WO2020252464A1
|
|
Populations of natural killer cells for treating cancers
|
|
WO2020190885A1
|
|
Placenta derived adherent cells for improved xenoplantation
|
|
WO2020113234A1
|
|
Placenta-derived allogeneic car-t cells and uses thereof
|
|
WO2020113182A1
|
|
Expansion of natural killer cells and ilc3 cells with novel aromatic compounds
|
|
WO2020113178A1
|
|
Aromatic compounds for use in activating hematopoietic stem and progenitor cells
|
|
WO2019165320A1
|
|
Post partum tissue-derived induced pluripotent stem cells and uses thereof
|
|
AU2018370157A1
|
|
Cultivation of placenta to isolate exosomes
|
|
WO2019067792A1
|
|
Tumor suppression using human placenta-derived intermediate natural killer (pink) cells in combination with an antibody
|
|
AU2017386790A1
|
|
Genetically modified natural killer cells
|
|
WO2018106742A1
|
|
Treatment of lymphedema and related conditions using placental adherent cells
|
|
CA3023239A1
|
|
Methods of treating acute myeloid leukemia and multiple myeloma using natural killer cells
|
|
CN109310710A
|
|
Natural killer cells and ILC3 cell and application thereof
|
|
CA2998759A1
|
|
Treatment of diabetic peripheral neuropathy using placental cells
|
|
MX2017015145A
|
|
Placental-derived stem cells to restore the regenerative engine, correct proteomic defects and extend lifespan.
|
|
AU2016268322A1
|
|
Angiogenesis using stimulated placental stem cells
|
|
AU2015374055A1
|
|
Natural killer cells and uses thereof
|
|
EP3360585A1
|
|
Improved method of making extracellular matrix compositions
|
